{"pub": "thehill", "url": "https://thehill.com/regulation/court-battles/464977-johnson-johnson-ordered-to-pay-8b-in-case-tied-to-antipsychotic-drug", "downloaded_at": "2019-10-09 18:40:52.564925+00:00", "title": "Johnson & Johnson ordered to pay $8B in case tied to antipsychotic drug", "language": "en", "text": "A jury on Tuesday said drugmaker Johnson & Johnson must pay $8 billion to a man who accused the company of failing to properly warn that its antipsychotic Risperdal could cause breast growth in men, according to Reuters.\n\nNicholas Murray had previously been awarded $1.75 million in the case in 2015 after a jury found the company failed to warn of the risk of the condition, gynecomastia. While a Pennsylvania appeals court upheld the verdict last February, it reduced it to $680,000.\n\nADVERTISEMENT\n\nPlaintiffs in the mass tort case were previously prohibited under a 2014 ruling that found a New Jersey law prohibiting punitive damages should apply to all cases, as J&J is headquartered in New Jersey.\n\nHowever, Pennsylvania Superior Court ruled in 2018 that the law of each plaintiff\u2019s state should apply instead.\n\n\u201cThis jury, as have other juries in other litigations, once again imposed punitive damages on a corporation that valued profits over safety and profits over patients,\u201d Murray\u2019s attorneys, Tom Kline and Jason Itkin, said in a joint statement.\n\n\u201cJohnson & Johnson and Janssen chose billions over children,\u201d they added, referencing the subsidiary that produces the drug.\n\nJ&J called the amount \u201cgrossly disproportionate with the initial compensatory award in this case,\u201d saying \u201cthe company is confident it will be overturned.\u201d\n\nThe figure will likely be reduced on appeal, according to Carl Tobias, a professor at the University of Richmond School of Law, who cited a Supreme Court decision finding \u201cfew awards exceeding a single-digit ratio between punitive and compensatory damages, to a significant degree, will satisfy due process.\u201d", "description": "A jury on Tuesday said drugmaker Johnson & Johnson must pay $8 billion to a man who accused the company of failing to properly warn that its antipsychotic Risperdal could cause breast growth in men,", "authors": [], "top_image": "https://thehill.com/sites/default/files/gavel_istock_0.jpg", "published_at": "2019-10-09"}